NANOVIRICIDES, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
NANOVIRICIDES, INC. (NNVC) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $1.65 million for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-05-15
- NANOVIRICIDES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-09-30 was -$432.85K.
- NANOVIRICIDES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-09-30 was -$931.49K.
- NANOVIRICIDES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-09-30 was -$1.18M.
- NANOVIRICIDES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-09-30 was -$1.15M.
- NANOVIRICIDES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$3.24M.
- NANOVIRICIDES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$3.35M.
- NANOVIRICIDES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$5.92M.
- NANOVIRICIDES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$6.45M, a 194.74% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.65M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $3.59M 10-Q · filed 2026-02-17 | |||
| 2025-09-30 | -$432.85K 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$3.24M 10-K · filed 2025-09-29 | |||
| 2025-03-31 | -$2.26M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$839.73K 10-Q · filed 2026-02-17 | |||
| 2024-09-30 | -$931.49K 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$3.35M 10-K · filed 2025-09-29 | |||
| 2024-03-31 | -$4.89M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$2.90M 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | -$1.18M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$5.92M 10-K · filed 2024-09-27 | |||
| 2023-03-31 | -$4.42M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$2.62M 10-Q · filed 2024-02-14 | |||
| 2022-09-30 | -$1.15M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$6.45M 10-K · filed 2023-10-13 | |||
| 2022-03-31 | -$4.94M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$3.18M 10-Q · filed 2023-02-14 | |||
| 2021-09-30 | -$819.88K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $6.81M 10-K · filed 2022-10-13 | |||
| 2021-03-31 | $9.19M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $4.68M 10-Q · filed 2022-02-14 | |||
| 2020-09-30 | $8.08M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $11.15M 10-K · filed 2021-10-12 | |||
| 2020-03-31 | $3.55M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$1.85M 10-Q · filed 2021-02-16 | |||
| 2019-09-30 | -$1.68M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | -$4.53M 10-K · filed 2021-10-12 | |||
| 2019-03-31 | -$2.84M 10-Q · filed 2020-06-22 | |||
| 2018-12-31 | -$3.18M 10-Q · filed 2020-02-14 | |||
| 2018-09-30 | -$999.41K 10-Q · filed 2019-11-15 | |||
| 2018-06-30 | -$8.02M 10-K · filed 2020-10-13 | |||
| 2018-03-31 | -$4.48M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$3.05M 10-Q · filed 2019-02-14 | |||
| 2017-06-30 | -$9.06M 10-K · filed 2019-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |